This trial aimed to assess the antitumor activity, safety, and predictive biomarkers of camrelizumab combined with apatinib and chemotherapy in previously untreated patients with AFP-producing G/GEJ (AFP-G/GEJ) adenocarcinoma. This evidence concerns the gene AFP and adenocarcinoma.